What Is GHK-Cu? The Copper Peptide Science, Explained
TL;DR: GHK-Cu is the copper(II) chelate of glycyl-L-histidyl-L-lysine, a tripeptide naturally present in human plasma that declines with age. It is one of the most extensively studied copper-binding peptides in cosmetic science, with documented actions in collagen and glycosaminoglycan synthesis, extracellular matrix remodeling, and broad gene-expression modulation. It appears in topical cosmetic products as a regulated cosmetic ingredient. It is not FDA approved as a drug and is not listed as a specifically named prohibited substance on the WADA Prohibited List.
Research-Use Disclaimer: This article is for educational and research reference purposes only. GHK-Cu is a research compound. In topical cosmetic applications it is regulated as a cosmetic ingredient; it is not approved by the FDA as a drug for any therapeutic indication. This content does not constitute medical advice, does not recommend or endorse human administration of any compound as a therapeutic agent, and does not describe protocols for personal use. All study findings described below refer to published scientific research. For adults 18+ with a research interest only.
What Is GHK-Cu? Definition and Origins
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine (sequence: Gly-His-Lys), complexed with a copper(II) ion. The parent tripeptide GHK occurs naturally in human plasma, saliva, and urine, and was first isolated and characterized in 1973 by Loren Pickart, who identified it as a factor in human albumin that caused old human liver tissue to synthesize proteins at rates resembling younger tissue.
GHK has an exceptionally high affinity for copper(II) ions. When chelated, the resulting GHK-Cu complex is the biologically active form most commonly referenced in the research literature. Plasma concentrations of GHK are estimated to average approximately 200 ng/mL at age 20, declining to roughly 80 ng/mL by age 60 — a trajectory described by Dou et al. (2020) in Aging Pathobiology and Therapeutics as a rationale for further investigation of the peptide in the context of age-associated changes.
In the Legendary Labz Peptide Research Guide, GHK-Cu is categorized within the Tissue Repair & Skin Research cluster. Notably, GHK-Cu occupies a distinct position relative to most research peptides: it has substantially more human-use data — particularly from the cosmetic and dermatological literature — than compounds studied exclusively in preclinical rodent models. This body of evidence shapes its evidence-tier assessment.
What Mechanisms Has GHK-Cu Research Documented?
GHK-Cu's research profile spans multiple biological mechanisms. Unlike many research peptides with a single proposed receptor target, GHK-Cu's literature documents a range of downstream effects, with Pickart and colleagues proposing broad gene-expression modulation as a unifying explanation. The key documented mechanisms are outlined below.
1. Collagen and Extracellular Matrix Stimulation
One of the foundational findings in GHK-Cu research is its capacity to stimulate connective tissue accumulation in vivo. A landmark 1993 study by Maquart et al., published in the Journal of Clinical Investigation, used a subcutaneous wound chamber model in rats and reported concentration-dependent increases in dry weight, total protein, collagen, DNA, and glycosaminoglycan content in GHK-Cu-injected chambers. Collagen synthesis was stimulated at twice the rate of non-collagen proteins, and type I and type III collagen mRNAs were elevated, while TGF-β mRNAs were not — suggesting a mechanism independent of classical TGF-β collagen induction (PMID: 8227353).
A 1992 study by Wegrowski et al. in Life Sciences further documented that GHK-Cu induced a dose-dependent increase in glycosaminoglycan (GAG) synthesis in normal human fibroblast cultures, with a biphasic response peaking at 10−9 to 10−8 M. The effect was most pronounced for extracellular dermatan sulfate and cell-layer heparan sulfate. The authors proposed GAG stimulation as one mechanism underlying the peptide's wound-healing properties (PMID: 1522753).
2. Matrix Metalloproteinase Modulation
A 1999 study by Siméon et al. in the Journal of Investigative Dermatology examined GHK-Cu's effects on matrix metalloproteinase (MMP) expression in rat wound chambers. The research found that while GHK-Cu did not alter interstitial collagenase activity, it increased pro-MMP-2 and activated MMP-2 during later stages of healing, suggesting a role in the remodeling phase of wound repair rather than initial collagen deposition alone (PMID: 10383745). This bidirectional regulation — stimulating both synthesis and breakdown of matrix components — is a consistently cited feature of GHK-Cu's proposed mechanism and appears in Pickart et al.'s 2015 review in BioMed Research International.
3. Broad Gene Expression Modulation
A key theme in Pickart and Margolina's published reviews is GHK-Cu's proposed capacity to modulate a large number of human genes. A 2015 review by Pickart, Vasquez-Soltero, and Margolina in BioMed Research International synthesized decades of in vitro and in vivo research, describing GHK-Cu as capable of up- and downregulating at least 4,000 human genes in cell-culture and rodent models, including genes associated with collagen synthesis, metalloproteinase activity, skin regeneration, and wound repair. The review also documented cosmetic-application findings including observations of improved skin elasticity, reduced photodamage, and increased keratinocyte proliferation in product-use studies (PMID: 26236730).
A 2012 review by the same authors in Oxidative Medicine and Cellular Longevity traced GHK's discovery to its broad gene-regulation profile, proposing that the peptide's ability to up- and downregulate large numbers of human genes critical for neuronal development, antioxidant defense, and maintenance of tissue homeostasis warranted further investigation (PMID: 22666519).
4. Antioxidant and Anti-Inflammatory Activity
Multiple studies have examined GHK-Cu's antioxidant and anti-inflammatory properties. A 2019 study by Ma et al. in Life Sciences investigated GHK-Cu in a bleomycin-induced pulmonary fibrosis mouse model, finding that GHK-Cu reduced inflammatory cytokines (TNF-α and IL-6), inhibited oxidative stress markers, and partially suppressed fibrotic progression via Nrf2, NF-κB, and TGF-β1/Smad2/3 pathways (PMID: 31809714). A 2026 study by Hu et al. in the European Journal of Pharmacology using a zebrafish larvae model found that GHK-Cu decreased neutrophil and macrophage migration, suppressed pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reduced reactive oxygen species, and downregulated the JAK1 pathway, characterizing the compound as a dual anti-inflammatory and antioxidant cosmetic ingredient candidate (PMID: 41997403).
5. Wound Healing and Angiogenic Activity
In addition to the collagen-synthesis findings, GHK-Cu has been studied in angiogenic and wound-closure contexts. A 2022 study by Yang et al. in Macromolecular Bioscience investigated a GHK-functionalized hydrogel scaffold in healthy and diabetic mouse wound models, reporting significantly accelerated wound closure, collagen deposition, tissue remodeling, and upregulated eNOS and CD31 expression in the treatment group (PMID: 35598070). A 2025 study by Chen et al. in Biomaterials Research evaluated a GHK-Cu-loaded hydrogel dressing, documenting antibacterial, anti-inflammatory, hemostatic, and neovascularization-promoting effects in an infected wound model (PMID: 39902373).
A 2014 preformulation study by Badenhorst et al. in Pharmaceutical Development and Technology characterized GHK-Cu's physicochemical properties relevant to topical delivery, finding it to be highly hydrophilic (log D between −2.38 and −2.49 at physiological pH) and relatively stable at neutral-to-acidic pH, providing foundational data for topical formulation development (PMID: 25384620; DOI: 10.3109/10837450.2014.979944).
What Is GHK-Cu's Evidence Tier? An Honest Assessment
GHK-Cu's evidence landscape is notably different from most research peptides studied exclusively in rodent injury models. Its cosmetic-ingredient status means a meaningful body of human-use observational and small-scale clinical data exists alongside the preclinical literature. The following table summarizes the documented evidence as of 2026.
| Evidence Level | Status for GHK-Cu (as of 2026) |
|---|---|
| Human randomized controlled trials (drug indication) | Not available for any therapeutic drug indication |
| Human cosmetic / clinical-grade studies | Present — topical-use studies on skin elasticity, fine lines, photodamage; more human data than most research peptides |
| Peer-reviewed animal / rodent model studies | Substantial — wound chambers, pulmonary fibrosis, diabetic wound models |
| In vitro / cell culture evidence | Extensive — fibroblast, collagen, GAG synthesis; gene-expression microarray data |
| FDA regulatory status | Cosmetic ingredient (topical); NOT approved as a drug for any indication |
| WADA status | Not listed as a specifically named prohibited substance on the 2026 Prohibited List |
Critical context: GHK-Cu's topical cosmetic-ingredient status is meaningfully different from its use as a systemic or injectable research compound. Cosmetic-use data (topical application, skin outcomes) does not establish efficacy or safety for systemic use. In vitro gene-expression data, while striking in breadth, reflects cell-culture conditions that may not translate to in vivo human biology. The evidence base is stronger than many research peptides at the observational and in vitro level, but large drug-indication RCTs have not been conducted.
What Is GHK-Cu's Regulatory Status?
FDA (United States)
GHK-Cu is used as a cosmetic ingredient in the United States, where it is regulated under the FDA's cosmetic framework — meaning manufacturers are not required to demonstrate efficacy before sale, and label claims are limited to cosmetic (not drug) claims. GHK-Cu is not approved as a drug for any therapeutic indication. It has no IND (Investigational New Drug) designation on record for human drug development, no authorized therapeutic dosing protocol, and no approved drug label. Regulatory status should be verified against current FDA guidance, as it is subject to change.
WADA (World Anti-Doping Agency)
Based on the 2026 WADA Prohibited List, GHK-Cu (glycyl-L-histidyl-L-lysine-copper) is not listed as a specifically named prohibited substance. This differs from compounds such as BPC-157, which are explicitly named under Section S0. However, athletes subject to WADA rules should consult the current Prohibited List and their national anti-doping organization directly, as the S0 category prohibits any pharmacological substance not approved by a regulatory authority for human therapeutic use when that substance is used as a drug, and the list is updated annually.
Frequently Asked Questions About GHK-Cu
What is GHK-Cu?
GHK-Cu is the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine, naturally present in human plasma. Plasma levels average approximately 200 ng/mL at age 20 and decline to roughly 80 ng/mL by age 60. The chelated form (GHK-Cu) is the biologically active version documented in extracellular matrix remodeling, collagen synthesis, antioxidant, and broad gene-expression research contexts.
Is GHK-Cu FDA approved?
GHK-Cu is not FDA approved as a drug for any therapeutic indication. It is regulated as a cosmetic ingredient when used in topical products in the United States. No approved drug label, authorized therapeutic dosing protocol, or IND designation exists for human drug use.
Is GHK-Cu on the WADA Prohibited List?
As of the 2026 WADA Prohibited List, GHK-Cu is not listed as a specifically named prohibited substance. Athletes subject to WADA rules should verify against the current list and consult their national anti-doping authority, as the S0 category has broad scope and the list changes annually.
What does the GHK-Cu research actually show?
Based on articles retrieved from PubMed, the peer-reviewed literature documents GHK-Cu's association with increased collagen and glycosaminoglycan synthesis in vitro, MMP modulation in wound-chamber models, upregulation of thousands of human genes in cell-culture studies, antioxidant and anti-inflammatory activity across zebrafish and mouse models, and accelerated wound closure in diabetic animal models. GHK-Cu also has more human cosmetic-application data than most research peptides, including topical-use observations of improved skin firmness and reduced photodamage. Large placebo-controlled drug-indication RCTs have not been conducted.
Go deeper: This compound is one of 48 documented in the Legendary Labz Peptide Research Guide — a 224-page, evidence-tiered reference with primary citations throughout. Read a free compound profile.
Research use only. Not intended for human use as a drug or therapeutic agent. Not FDA approved as a drug. GHK-Cu is regulated as a cosmetic ingredient in topical products; it has no approved drug indication. This article documents published scientific literature for educational and reference purposes and is not medical advice; nothing here is intended to diagnose, treat, cure, or prevent any disease, or to recommend human use of any compound as a therapeutic agent. All citations link to primary sources — read them in full. Must be 18+.